Core Laboratories Inc. (NYSE:CLB – Get Free Report)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $13.07, but opened at $13.76. Core Laboratories shares last traded at $13.53, with a volume of 20,938 shares.
Core Laboratories News Roundup
Here are the key news stories impacting Core Laboratories this week:
- Positive Sentiment: Zacks Research lifted its longer-term outlook for Core Laboratories (CLB), including FY2027 EPS of $0.83 and FY2028 EPS of $1.10, both above the current full-year consensus of $0.54 per share. Core Laboratories Inc. stock page
- Positive Sentiment: The firm also sees Core Laboratories earning $0.57 per share in FY2026, slightly above the consensus estimate of $0.54, suggesting analysts expect earnings momentum to improve in the near term. Core Laboratories Inc. stock page
- Neutral Sentiment: Updated quarterly estimates for 2026–2028 were largely consistent across the notes, with Q2 2026 at $0.07 EPS, Q3 2026 at $0.18 EPS, and Q4 2026 at $0.27 EPS, reinforcing a steady but gradual recovery profile. Core Laboratories Inc. stock page
Wall Street Analyst Weigh In
Several analysts recently weighed in on the stock. Weiss Ratings cut shares of Core Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Wall Street Zen raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a research note on Sunday. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $12.00.
Core Laboratories Trading Up 0.0%
The company has a quick ratio of 1.50, a current ratio of 2.05 and a debt-to-equity ratio of 0.42. The company has a market cap of $632.54 million, a P/E ratio of 21.11, a PEG ratio of 2.72 and a beta of 0.99. The firm’s 50 day moving average is $15.78 and its two-hundred day moving average is $16.70.
Core Laboratories (NYSE:CLB – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The oil and gas company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. The company had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $122.99 million. Core Laboratories had a net margin of 5.94% and a return on equity of 11.52%. Core Laboratories’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 earnings per share. Core Laboratories has set its Q2 2026 guidance at 0.060-0.120 EPS. As a group, equities research analysts anticipate that Core Laboratories Inc. will post 0.54 EPS for the current year.
Core Laboratories Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Monday, May 11th will be issued a $0.01 dividend. The ex-dividend date is Monday, May 11th. This represents a $0.04 annualized dividend and a yield of 0.3%. Core Laboratories’s payout ratio is presently 6.15%.
Hedge Funds Weigh In On Core Laboratories
Several hedge funds and other institutional investors have recently bought and sold shares of CLB. Summit Securities Group LLC acquired a new position in Core Laboratories in the first quarter valued at $31,000. Aster Capital Management DIFC Ltd acquired a new position in Core Laboratories in the fourth quarter valued at $34,000. Quarry LP lifted its holdings in Core Laboratories by 118.1% in the third quarter. Quarry LP now owns 2,953 shares of the oil and gas company’s stock valued at $36,000 after buying an additional 1,599 shares during the period. CWM LLC lifted its holdings in Core Laboratories by 36.1% in the fourth quarter. CWM LLC now owns 2,516 shares of the oil and gas company’s stock valued at $40,000 after buying an additional 668 shares during the period. Finally, Hantz Financial Services Inc. lifted its holdings in Core Laboratories by 124.7% in the fourth quarter. Hantz Financial Services Inc. now owns 3,177 shares of the oil and gas company’s stock valued at $51,000 after buying an additional 1,763 shares during the period. Institutional investors and hedge funds own 97.81% of the company’s stock.
Core Laboratories Company Profile
Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.
The company’s portfolio spans two primary service lines: reservoir description and production enhancement.
Featured Stories
- Five stocks we like better than Core Laboratories
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
